I'm trying to understand the efficacy of ofatumumab vs Ibrutinib with the data shown in the corporate presentation. Specifically:
- Slide 15 shows Ibrutinib ORR at 81% for Monotherapy. - Slide 20 shows combination Ibrutinib and ofatumumab ORR at 100%.
But I don't see any data showing ofatumumab as a monotherapy. Without that, how do we know how much better Ibrutinib is verses existing ofatumumab monotherapy? Generally data is presented such that the current approved therapy baseline is shown vs the improvement gained by adding the study drug. That allows one to gauge how much better the study drug is over current therapy.
Yep. Pretty impressive actually. I am the only flea capable of typing. And that's not all I can do. Glad to have annoyed you. Your "concern" has been addressed thoroughly and intelligently several times. Rather than being absurd you could take the opportunity to learn something that will help your investments in the future. Good day,
It's been really scary for me this month being a pcyc long. Anyway, nobody listen to this guy. I am a physician who has been critically reading and discussing clinical studies almost daily for many years. Tech trader is either a lay person trying to understand something way over their head or purposefully misleading. Either way it's pathetic, but at least we know he has missed out big here based on his posts.
That's great, but the oversight in the study design means we have to wait until Phase 3. And with this company approaching $4 Billion in marketcap it would be nice to know if OFA as a monotherapy isn't as good as Ibrutinib. Right now it's a guessing game. That's pretty scary.